Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) SVP Heidi L. Wagner sold 655 shares of the stock in a transaction on Monday, February 5th. The stock was sold at an average price of $117.26, for a total value of $76,805.30. Following the completion of the sale, the senior vice president now directly owns 32,635 shares in the company, valued at $3,826,780.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down $3.04 during mid-day trading on Thursday, reaching $114.11. The company had a trading volume of 1,872,629 shares, compared to its average volume of 1,969,899. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a market capitalization of $25,400.00, a PE ratio of 50.73, a P/E/G ratio of 0.96 and a beta of 1.16. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.27 by $0.21. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The business had revenue of $909.70 million during the quarter, compared to analysts’ expectations of $880.38 million. During the same quarter last year, the business posted $1.26 earnings per share. The company’s quarterly revenue was up 9.5% on a year-over-year basis. sell-side analysts expect that Alexion Pharmaceuticals, Inc. will post 4.82 EPS for the current year.
Several brokerages have weighed in on ALXN. Evercore ISI raised Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research report on Monday. Leerink Swann reaffirmed a “buy” rating and issued a $169.00 target price on shares of Alexion Pharmaceuticals in a research report on Wednesday, December 6th. Raymond James Financial reaffirmed an “outperform” rating and issued a $130.00 target price (down from $178.00) on shares of Alexion Pharmaceuticals in a research report on Thursday, January 4th. They noted that the move was a valuation call. Royal Bank of Canada raised their price target on Alexion Pharmaceuticals to $166.00 in a report on Tuesday, October 24th. Finally, TheStreet lowered Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Friday, November 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and twenty have given a buy rating to the company. Alexion Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $153.10.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.